Evidence map›Paper›PMID 37901790›Full record

ArticleFrontiers in aging neuroscience2023

Reducing the receipt of contraindicated medications in patients with Parkinson disease.

Caroline Goldin, Stefan Sillau, Elisa Worledge, Jarrett Bremmer, Robbie Cummins, Kathryn Tremolet de Villers, Michelle E Fullard

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Caroline GoldinDepartment of Neurology, Ochsner Medical Center, New Orleans, LA, United States.
Stefan SillauDepartment of Neurology, University of Colorado, Aurora, CO, United States.
Elisa WorledgeUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Denver Health, Denver, CO, United States.
Jarrett BremmerBaptist Health, Jacksonville, FL, United States.
Robbie CumminsDepartment of Neurology, University of Colorado, Aurora, CO, United States.
Kathryn Tremolet de VillersDepartment of Pharmacy, University of Colorado Hospital, Aurora, CO, United States.
Michelle E FullardDepartment of Neurology, University of Colorado, Aurora, CO, United States.
University of Colorado Anschutz Medical Campus · USBaptist Medical Center Jacksonville · USDenver Health Medical Center · USOchsner Medical Center · USUniversity of Colorado Hospital · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
NCATS NIH HHS UL1 TR002535
6 · The paper itself

Abstract

Background: The administration of antidopaminergic medications to patients with Parkinson's disease (PD) can exacerbate symptoms, and in the hospital setting, can lead to complications and increased length of stay. Despite efforts to improve medication administration through provider education and patient-centered interventions, the problem persists, with an estimated 21-43% of hospitalized PD patients receiving dopamine blocking medications. Methods: In this study, a best practice alert (BPA) was developed that was triggered when an antidopaminergic medication was ordered in the Emergency Department or hospital for a patient with a diagnosis of PD in the EMR. The primary outcomes were receipt of a contraindicated medication, length of stay (LOS) and readmission within 30 days. These outcomes were compared between the 12 months prior to the intervention and the 12 months post intervention. Data were also collected on admitting diagnosis, admitting service, neurology involvement and patient demographics. Results: For pre-intervention inpatient encounters, 18.3% involved the use of a contraindicated medication. This was reduced to 9.4% of all inpatient encounters for PD patients in the first 3 months post-intervention and remained lower at 13.3% for the full 12 months post-intervention. The overall rate of contraindicated medication use was low for ED visits at 4.7% pre-intervention and 5.7% post-intervention. Receipt of a contraindicated medication increased the risk of a longer length of stay, both before and after the intervention, but did not significantly affect 30-day readmission rate. Conclusion: An EMR BPA decreased the use of contraindicated medications for PD patients in the hospital setting, especially in the first 3 months. Strategies are still needed to reduce alert fatigue in order to maintain initial improvements.

Indexed as

best practice alertcontraindicated medicationselectronic medical recordParkinson ‘s diseasequality improvement

Identifiers

PMID37901790
PMCPMC10602692
OpenAlexW4387581102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.